Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Sargramostim in Advanced Melanoma
NCT04703426Phase 2Withdrawn
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2021
- Primary completion
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in melanoma, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Overall Response Rate at 12 weeks. Planned start Apr 2021; status: withdrawn.
02
Drugs
sargramostim
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04703426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04703426.